HLHaiying Li

Haiying Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Haiying Li has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Chongqing Tan

    Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, People’s Republic of China

    1 shared publication
  • Lidan Yi

    Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, People’s Republic of China

    1 shared publication
  • Qiao Liu

    Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, China

    1 shared publication
  • Xia Luo

    Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, People’s Republic of China

    1 shared publication
  • Xiaohui Zeng

    Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, China

    1 shared publication
  • Xiaomin Wan

    Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, People’s Republic of China

    1 shared publication

Latest Publications

  • Open Access

    Economic Evaluation of Adding Daratumumab to Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma

    by Lidan Yi, Qiao Liu, Chongqing Tan, Xiaomin Wan, Xia Luo, Yinbo Li, Haiying Li, Xiaohui Zeng

    Objective: To assess the cost-effectiveness of adding daratumumab to carfilzomib and dexamethasone (KdD) in patients with relapsed or refractory multiple myeloma (RRMM). Materials and Methods: A Markov model was established to estimate health and economic outcomes of carfilzomib and dexamethasone (Kd) with or without daratumumab for RRMM patients over a lifetime horizon. The patients and intervention of the two arms were modeled according to the CANDOR trial. Costs were collected from the Chinese health system perspective. One-way sensitivity analysis and probabilistic sensitivity analysis were performed to evaluate the robustness of our conclusions. Results: Compared with the Kd arm, KdD achieved an additional 0.537 quality-adjusted life-years (QALYs) at an incremental cost of $138,084, resulting in an incremental cost-utility ratios (ICURs) of $257,319 per QALY. Uncertainty analyses revealed that the model is robust to all the input parameters. Conclusion: From the Chinese healthcare system perspective, adding daratumumab to the Kd regimen for patients with RRMM appears to lack cost-effectiveness. Exploring alternative avenues such as negotiating for a more favorable price or introducing a financial assistance program dedicated to daratumumab and/or carfilzomib could prove to be an effective strategy in enhancing accessibility of this combination.